Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Phase 2/3 Recruiting 33 enrolled Shanghai Huaota Biopharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Timeline

Start: 2024-09-02
Primary completion: 2025-12-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HB0034	Monoclonal antibody	300 mg	Intravenous

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Summary

Timeline

Drugs

Indications